Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Dose-Titration, Open-Label Study Evaluating the Safety and Efficacy of BIV201 Compared to Standard of Care to Reduce Ascites and Complications in Cirrhotic Patients With Refractory Ascites

NCT04112199 is registered in ClinicalTrials.gov with BioVie Inc. as lead sponsor.

NCT NCT04112199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04112199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Dose-Titration, Open-Label Study Evaluating the Safety and Efficacy of BIV201 Compared to Standard of Care to Reduce Ascites and Complications in Cirrhotic Patients With Refractory Ascites
Lead sponsor
BioVie Inc.
Phase
Phase 2
Overall status
Terminated
Start date
June 17, 2021
Completion date
May 8, 2023
Enrollment
15 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

ascites, decompensated cirrhosis